How many Tofacitinib clinical trials are there?

189 Tofacitinib clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 32 are actively recruiting participants. 93 are marked completed.

Are Tofacitinib clinical trials recruiting in 2026?

Yes — 32 Tofacitinib trials are actively recruiting in 2026, with 47 U.S. sites across 24 states. See the recruiting trials and the per-state site list further down this page.

What conditions is Tofacitinib being studied for?

Tofacitinib is being studied for Rheumatoid Arthritis, Ulcerative Colitis, Healthy, Psoriatic Arthritis, Alopecia Areata and 142 more. The trials are grouped by indication on this page.

What phase is Tofacitinib in?

Tofacitinib clinical trials span 35 Phase 4, 27 Phase 3, 49 Phase 2, 25 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.

Who sponsors Tofacitinib clinical trials?

The lead sponsor across the most Tofacitinib trials is Pfizer, with 101 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.

Tofacitinib Clinical Trials (2026): 189 Studies for Rheumatoid Arthritis & Ulcerative Colitis

Creator: Hipa.ai Research
Published: 2026-05-08T19:19:52.659Z

Hipa.ai Research · Source: ClinicalTrials.gov / AACT

Synced daily from ClinicalTrials.gov via AACT. Last sync: June 16, 2026.

189 Tofacitinib clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 96 indications (including Rheumatoid Arthritis & Ulcerative Colitis) and 313,964 total planned enrollment. 27 Phase 3 Tofacitinib trials and 49 Phase 2, 35 Phase 4 are listed. 48 Tofacitinib clinical trials are actively recruiting at 47 U.S. sites across 24 states. Most recent activity: NCT07281456 (Dec 2030).

Where to Participate: All Tofacitinib Trial Sites in the U.S. (47 sites across 24 states)

Every actively recruiting Tofacitinibtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.

State	Facility	City	Trial	Map
AL	Digestive Health Specialsits	Dothan36301	NCT06095128	Map
AZ	GI Alliance Sun City	Sun City85351	NCT06095128	Map
CA	Cedars-Sinai Medical Center	Los Angeles90048	NCT06095128	Map
CA	Hoag Hospital Newport Beach	Newport Beach92663	NCT06095128	Map
CA	University of California San Francisco Pediatric Rheumatology	San Francisco94158	NCT06654882	Map
CA	Stanford University Medical Center	Stanford94305	NCT03681275	Map
FL	University of Florida	Gainesville32610	NCT06654882	Map
FL	Endoscopic Research Inc	Orlando32803	NCT06095128	Map
FL	Alliance Clinical Research of Tampa, LLC	Tampa33615	NCT06095128	Map
GA	Gastroenterology Consultants, P.C.	Roswell30076	NCT06095128	Map
IL	University of Chicago Medicine	Chicago60637	NCT06095128	Map
IL	GI Alliance - Illinois Gastroenterology Group - Glenview	Glenview60026	NCT06095128	Map
IL	GI Alliance - Illinois Gastroenterology Group LLC - Gurnee	Gurnee60031	NCT06095128	Map
KS	University of Kansas Medical Center	Kansas City66160	NCT06095128	Map
KY	University of Louisville	Louisville40202	NCT06095128	Map
LA	GI Alliance	Metairie70006	NCT06095128	Map
LA	Tulane University	New Orleans70112	NCT06095128	Map
MD	National Institutes of Health Clinical Center	Bethesda20892	NCT07281456	Map
MD	Capital Digestive Care - MGG Group - Chevy Chase Clinical Research	Chevy Chase20815	NCT06095128	Map
MI	Huron Gastroenterology Associates, P.C.	Ypsilanti48197	NCT06095128	Map
MN	MNGI Digestive Health, PA	Plymouth55446	NCT06095128	Map
MO	Mid-America Gastro-Intestinal Consultants	Kansas City64111	NCT06095128	Map
MO	BVL Clinical Research	Liberty64068	NCT06095128	Map
MO	Washington University School of Medicine	St Louis63110	NCT06095128	Map
NE	University of Nebraska Medical Center	Omaha68198	NCT03414502	Map
NJ	Hackensack Meridian Health - Joseph M. Sanzari Children's Hospital	Hackensack07601	NCT06654882	Map
NY	NYU Langone Health	New York10016	NCT06095128	Map
NY	Weill Cornell Medical College- New York Presbyterian Hospital	New York10065	NCT06095128	Map
NC	Digestive Health Partners	Asheville28801	NCT06095128	Map
NC	University of North Carolina	Chapel Hill27599	NCT06095128	Map
OH	University of Cincinnati	Cincinnati45627	NCT06095128	Map
OH	Nationwide Children's Hospital	Columbus43205	NCT06654882	Map
OH	Ohio Gastroenterology group, Inc.	Columbus43202	NCT06095128	Map
OH	Gastro Intestinal Research Institute of Northern Ohio, LLC.	Westlake44145	NCT06095128	Map
PA	Allegheny Health Network	Wexford15090	NCT06095128	Map
RI	University Gastroenterology	Providence02905	NCT06095128	Map
SD	Rapid City Medical Center, LLP	Rapid City57701	NCT06095128	Map
TX	GI Alliance - Digestive Health Associates of Texas	Dallas75044	NCT06095128	Map
TX	MD Anderson Cancer Center	Houston77030	NCT06698822	Map
TX	The University of Texas Health Science Center at Houston	Houston77030	NCT06095128	Map
TX	GI Alliance - Mansfield	Mansfield76063	NCT06095128	Map
TX	Gastroenterology Research of San Antonio, LLC	San Antonio78229	NCT06095128	Map
TX	Texas Digestive Disease Consultants (TDDC), Southlake	Southlake76092	NCT06095128	Map
TX	Tyler Research Institute, LLC	Tyler75701	NCT06095128	Map
TX	GI Alliance - Webster	Webster77598	NCT06095128	Map
UT	University of Utah Health	Salt Lake City84108	NCT06095128	Map
WA	Washington Gastroenterology- GIA	Tacoma98405	NCT06095128	Map

Tofacitinib clinical trials at a glance: phase × recruitment status

Phase	recruiting	active not recruiting	enrolling by invitation	completed	terminated	withdrawn	not yet recruiting	unknown	Total
Early P1	2			2	1		2		7
P1		1		24					25
P1/P2		1		4	1				6
P2	7	2		18	3	2	6	11	49
P2/P3				1				2	3
P3	4	4		15	1		1	2	27
P4	9		1	10	1		6	8	35
N/A	8		1	19			1	8	37

Recruiting Tofacitinib clinical trials (48)

Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).

NCT ID	Title	Phase	Indication	Enrollment	Started
NCT07281456	Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren Disease	P2	Sjogren's Syndrome	60	Dec 2025
NCT07352566	Utilization of a Microdevice for Psoriasis and Atopic Dermatitis	P4	Psoriasis	10	Aug 2026
NCT07522801	ALL-TARGETA Precision Medicine Trial for Patients With Relapsed or Refractory T Cell ALL	P2	LAL	93	Sep 2026
NCT06301373	Methotrexate Combined With Tofacitinib in Rheumatoid Arthritis	N/A	Rheumatoid Arthritis	130	Sep 2024
NCT06687551	JAK-TAPJAK Inhibitor Dose TAPering Strategy Study	P4	Rhumatoid Arthisis	308	Jan 2025
NCT04871191	SATELITEStudy of Salvage Therapy to Treat Patients With Granulomatosis With Polyangiitis	P3	Granulomatosis With Polyangiitis	42	Jun 2025
NCT03414502	Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response	P3	Rheumatoid Arthritis	400	Dec 2007
NCT07487311	GUSA Prospective Cohort Study Evaluating the Efficacy and Safety of Guselkumab (GUS) With JAK Inhibitors in Patients With Difficult-To-Treat Inflammatory Bowel Disease (IBD)	—	Inflamatory Bowel Disease	80	Jan 2026
NCT07530367	A Phase III Randomized Controlled Trial Evaluating the Efficacy and Safety of Tofacitinib Combined With Imatinib in Patients With Moderate-to-Severe Palmoplantar Pustulosis	P3	Palmoplantar Pustulosis (PPP)	135	Apr 2026
NCT07297069	Combination Therapy With Infliximab and Tofacitinib for Acute Severe Ulcerative Colitis - CINTO Trial	P2	Acute Severe Ulcerative Colitis	60	Jan 2026
NCT07547930	TOFA-GOTofacitinib for Glucocorticoid-Resistant Moderate-to-Severe Thyroid Eye Disease	P2	Thyroid Eye Disease, TED	8	Apr 2026
NCT07406035	A Phase II Clinical Trial to Evaluate the Efficacy and Safety of TQH3906 Capsules in the Treatment of Active Psoriatic Arthritis	P2	Psoriatic Arthritis	156	Apr 2026
NCT06707246	A Randomized Trial Comparing the Efficacy and Safety of Secukinumab with Tofacitinib in the Treatment of Moderate to Severe Hidradenitis Suppurativa in Chinese Patients	N/A	Hidradenitis Suppurativa	60	Dec 2024
NCT07138898	Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty	P2	Rheumatic Disease	80	Sep 2025
NCT06095128	UCA Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)	P4	Ulcerative Colitis	65	Jun 2024
NCT07343635	The Efficacy and Safety of Anti-inflammation Treatment (Hirudoid Introduction Followed by Yellow Light Therapy) Combined With Tofacitinib and Doxycycline in Chinese Adult Patients With Mild to Moderate Erythematous Telangiectatic Rosacea	N/A	Erythematotelangiectatic Rosacea	186	Feb 2026
NCT06498089	A Randomized, Controlled, Open-label, Multicenter Clinical Trial Comparing the Efficacy and Safety of a Precision Treatment Regimen Based on Clinical-molecular Phenotypes with a Conventional Treatment Regimen in the Treatment of Patients with Active Takayasu's Arteritis	P4	Takayasu Arteritis	124	Jun 2024
NCT07131813	Evaluation of Efficacy and Safety of add-on Tofacitinib in Patients With Oral Lichen Planus	P4	Oral Lichen Planus	60	Oct 2025
NCT05845723	Tocilizumab and Tofacitinib in the Treatment of Vascular Behçet's Syndrome	P2	Aneurysm	81	Jun 2023
NCT06945666	A Study of Iguratimod in Combination With Tofacitinib in RA Patients	P4	Rheumatoid Arthritis (RA	200	Aug 2025
NCT06979271	Efficacy and Safety of Telitacicept Combined With Tofacitinib for Refractory Rheumatoid Arthritis	—	Telitacicept	20	Jun 2025
NCT07313072	Topical Use of 2% Tofacitinib for Nail Psoriasis: an Exploratory Clinical Study	P2	Nail Psoriasis	10	Mar 2026
NCT07055529	(PUVA)Comparison of Efficacy and Safety Psoralen Combined With Ultraviolet A (PUVA) Vs Tofacitinib in the Treatment of Generalized Vitiligo.	Early P1	Vitiligo, Generalized	64	Jun 2026
NCT06654882	SMART-JIATrial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis	P3	Polyarticular Course Juvenile Idiopathic Arthritis (JIA)	400	Jan 2026
NCT07211932	Tofacitinib in Juvenile Idiopathic Arthritis	—	Juvenile Idiopathic Arthritis (JIA)	58	Dec 2025
NCT06573593	Efficacy and Safety of JAK Inhibitors in Patients With AA: RWE Study	—	Alopecia Areata	150	Jul 2024
NCT06438679	3T Therapy in the Treatment of MDA5-positive Dermatomyositis	P4	Dermatomyositis	133	Mar 2024
NCT05186623	Prediction Model for Response to Biologics and Small Molecular Agent for UC	—	Ulcerative Colitis	300	Feb 2022
NCT06688838	inapplicableEffective Treatment of Jak1/3 Inhibitor in Blau Syndrome	—	Blau Syndrome	24	Jan 2017
NCT06393972	The Efficacy and Safety of Tofacitinib in Patients With Glucocorticoid Resistant ICIs-related Myocarditis	P2	Glucocorticoid Resistant ICIs-related Myocarditis	25	Jul 2024
NCT03681275	Janus Kinase Inhibition to Prevent Ventilator-induced Diaphragm Dysfunction	P2	Diaphragm Injury	70	Sep 2019
NCT06698822	CTCLA Phase 2 Trial to Assess Safety and Efficacy of Tofacitinib 2% Cream in the Treatment of Cutaneous T-cell Lymphoma (CTCL), Stages IA, IB, and IIA	P2	Cutaneous T-Cell Lymphoma	20	Mar 2025
NCT07554820	TOFSTATMajor Adverse Cardiovascular Events (MACE) in Rheumatoid Arthritis Patient With Moderate to Severe Disease Activity Treated With Tofacitinib and Statins vs TNF Inhibitors: TOFSTAT CLINICAL TRIAL	P4	Rheumatoid Arthritis	120	Dec 2025
NCT06119490	TENEvaluation of the Efficacy and Safety of Methylprednisolone Combined With the JAK Inhibitors in the Treatment of Toxic Epidermal Necrolysis	Early P1	Toxic Epidermal Necrolysis	30	Jul 2023
NCT06176508	Efficacy and Safety of HS-10374 Compared to Placebo in Adults With Active Psoriatic Arthritis	P2	Psoriatic Arthritis	160	Feb 2024
NCT07406204	TOFA-MTX-AATofacitinib vs Methotrexate for Severe Alopecia Areata (TOFA-MTX-AA)	P4	Alopecia Areata	78	Feb 2026
NCT06465732	Efficacy and Safety of Dupilumab in Combination With Tofacitinib in Moderate to Severe Adult AD Patients	P4	Atopic Dermatitis	220	Jan 2025
NCT06112665	FASTLANEToFAcitinib in Early Active Axial SpondyloarThritis:	P4	Axial Spondyloarthritis	104	Nov 2023
NCT04876781	XRPMSKorean Post-marketing Surveillance for Xeljanz XR	—	Active Moderate to Severe Rheumatoid Arthritis	200	Jan 2022
NCT06689982	TALENTTofacitinib in Patients With Amyotrophic Lateral Sclerosis	Early P1	Amyotrophic Lateral Sclerosis	12	Dec 2024
NCT06625450	TOFACITINIB vs TOFACITINIB WITH MESALAMINE IN ULCERATIVE COLITIS	P4	Ulcerative Colitis	75	Oct 2024
NCT06172361	ITTGPMRInduction and Tapering Therapy With Tofacitinib and Glucocorticoid in Patients With Polymyalgia Rheumatica	P3	Polymyalgia Rheumatica	98	Jan 2024
NCT06998875	A Prospective Cohort Study on Primary Cutaneous Amyloidosis	P4	Primary Cutaneous Amyloidosis	56	Mar 2025
NCT05313620	Effect of Tofacitinib on Coagulation and Platelet Function, and Its Role in Thromboembolic Events	P4	Ulcerative Colitis	30	Apr 2022
NCT05102448	Comparison of Tofacitinib and Methotrexate in Takayasu's Arteritis	P4	Takayasu Arteritis	76	Nov 2021
NCT07261306	MTXComparison Between Oral Methotrexate and Tofacitinib in Chronic Plaque Psoriasis	Early P1	Psoriasis	75	Aug 2025
NCT05348213	R-ICE+XNovel Targeted Drugs Combined With R-ICE Regimen in Relapsed and Refractory Diffuse Large B-cell Lymphoma	P2	Diffuse Large B Cell Lymphoma	76	May 2022
NCT03976245	RAAdvanced Therapeutics in Rheumatoid Arthritis (RA)	P4	Rheumatoid Arthritis	144	Mar 2020

Tofacitinib clinical trials by indication

Rheumatoid Arthritis (34)

NCT	Acronym	Phase	Status	Title
NCT06301373	—	N/A	recruiting	Methotrexate Combined With Tofacitinib in Rheumatoid Arthritis
NCT03414502	—	P3	recruiting	Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response
NCT06020144	TARA	P3	active not recruiting	A Phase 3 Study Comparing TLL-018 to Tofacitinib in RA Subjects With Inadequate Response or Intolerance to bDMARDs
NCT07554820	TOFSTAT	P4	recruiting	Major Adverse Cardiovascular Events (MACE) in Rheumatoid Arthritis Patient With Moderate to Severe Disease Activity Treated With Tofacitinib and Statins vs TNF Inhibitors: TOFSTAT CLINICAL TRIAL
NCT05803135	—	P4	unknown	Iguratimod Combined With Tofacitinib in the Treatment of Rheumatoid Arthritis
NCT03755466	—	P2	unknown	Examination of Efficacy and Safety of Baricitinib in RA Patients
NCT03976245	RA	P4	recruiting	Advanced Therapeutics in Rheumatoid Arthritis (RA)
NCT05246293	RAILDTo	P2	unknown	Tofacitinib in the Treatment of Rheumatoid Arthritis-related Interstitial Lung Disease.
+ 26 more, see All trials below.

Ulcerative Colitis (12)

NCT	Acronym	Phase	Status	Title
NCT04624230	—	P3	active not recruiting	Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis
NCT06095128	UC	P4	recruiting	A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)
NCT05186623	—	N/A	recruiting	Prediction Model for Response to Biologics and Small Molecular Agent for UC
NCT05112263	TOCASU	N/A	unknown	Tofacitinib Versus Cyclosporine for Steroid Refractory Acute Severe Ulcerative Colitis
NCT06625450	—	P4	not yet recruiting	TOFACITINIB vs TOFACITINIB WITH MESALAMINE IN ULCERATIVE COLITIS
NCT05313620	—	P4	recruiting	Effect of Tofacitinib on Coagulation and Platelet Function, and Its Role in Thromboembolic Events
NCT04424303	TOFAST	N/A	completed	Tofacitinib in Adult Patients With Moderate to Severe Ulcerative Colitis
NCT04338204	ODEN	N/A	completed	Observational Study To Assess The Effectiveness and Treatment Adherence Of Tofacitinib of Ulcerative Colitis In Clinical Practice In Sweden
+ 4 more, see All trials below.

Healthy (11)

NCT	Acronym	Phase	Status	Title
NCT04985955	—	P1	completed	A Study Validating the Use of Candin as a Challenge Agent in Healthy Participants - Intervention Specific Appendix 3
NCT04552197	—	P1	completed	A Study of JNJ-64251330 in Healthy Participants
NCT04338711	QD	P1	completed	A Study In Adult Healthy Volunteers To Asses Once Daily (QD) Dosing With The Selected Age-Appropriate Modified Release (MR) Formulations
NCT04111614	—	P1	completed	A Study to Demonstrate the Equivalence of the Tofacitinib Oral Solution to the Tablet Formulation in Healthy Participants.
NCT04403776	—	P1	completed	PK and Bioavailability Comparison of Tofacitinib Between a Modified Release and The Immediate Release Formulation
NCT03112148	—	P1	completed	PK Study in Adult Healthy Volunteers to Assess QD Dosing With the Selected Age-appropriate MR Formulations
NCT02487433	—	P1	completed	A Study To Evaluate The Effect Of Food On The Behavior of Tofacitinib Modified Release 22 Milligram Tablets In Healthy Volunteers
NCT02084875	—	P1	completed	A Study To Evaluate The Effect Of Food On The Behavior Of Tofacitinib Modified Release 11 Milligram Tablets In Healthy Western And Japanese Volunteers
+ 3 more, see All trials below.

Psoriatic Arthritis (8)

NCT	Acronym	Phase	Status	Title
NCT07406035	—	P2	not yet recruiting	A Phase II Clinical Trial to Evaluate the Efficacy and Safety of TQH3906 Capsules in the Treatment of Active Psoriatic Arthritis
NCT06176508	—	P2	recruiting	Efficacy and Safety of HS-10374 Compared to Placebo in Adults With Active Psoriatic Arthritis
NCT04610476	—	P3	unknown	Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic Arthritis
NCT04062695	PASTOR	P2	unknown	Tofacitinib for Reduction of Spinal Inflammation in Patients With Psoriatic ArthritiS PresenTing With Axial InvOlvement
NCT03486457	—	P3	completed	Efficacy And Safety Of Tofacitinib In Chinese Subjects With Active Psoriatic Arthritis
NCT03736161	PsOLSET-BD	P3	completed	Safety and Efficacy of Tofacitinib vs Methotrexate in the Treatment of Psoriatic Arthritis
NCT01882439	OPAL BEYOND	P3	completed	Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors
NCT01877668	OPAL BROADEN	P3	completed	Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study

Alopecia Areata (7)

NCT	Acronym	Phase	Status	Title
NCT06573593	—	N/A	recruiting	Efficacy and Safety of JAK Inhibitors in Patients With AA: RWE Study
NCT07406204	TOFA-MTX-AA	P4	not yet recruiting	Tofacitinib vs Methotrexate for Severe Alopecia Areata (TOFA-MTX-AA)
NCT06278402	—	P3	completed	Efficacy of Oral Tofacitinib in Moderate to Severe Alopecia Areata, Totalis and Universalis at Tertiary Care Hospital, Karachi.
NCT03800979	—	P4	completed	Effectiveness and Safety of Tofacitinib in Patients With Extensive and Recalcitrant Alopecia Areata
NCT02812342	—	P2	completed	Topical Tofacitinib for the Treatment of Alopecia Areata and Its Variants
NCT02299297	—	P2	completed	Study To Evaluate The Efficacy Of Tofacitinib In Moderate To Severe Alopecia Areata, Totalis And Universalis
NCT02312882	—	N/A	completed	Tofacitinib for the Treatment of Alopecia Areata and Its Variants

Arthritis, Rheumatoid (6)

NCT	Acronym	Phase	Status	Title
NCT04928066	TF	P4	completed	The Efficacy and Safety of Tofacitinib (TF) With Iguratimod (IGU) on RA
NCT03387423	ESCALATE-RA	N/A	completed	Observational Study to Determine How Physicians Make Treatment Decisions in Patients Treated With Tofacitinib for Moderate to Severe Active Rheumatoid Arthritis
NCT03981900	—	N/A	completed	IDentification of Factors Predictive of Tofacitinib's Survival in Patient With Rheumatoid Arthritis
NCT03970837	contRAst 2	P3	terminated	Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic (cs)/Biologic (b) Disease Modifying Anti-rheumatic Drugs (DMARDs)
NCT03980483	contRAst 1	P3	completed	Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate
NCT02092467	TNF	P4	completed	Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis

Takayasu Arteritis (5)

NCT	Acronym	Phase	Status	Title
NCT06498089	—	P4	recruiting	A Randomized, Controlled, Open-label, Multicenter Clinical Trial Comparing the Efficacy and Safety of a Precision Treatment Regimen Based on Clinical-molecular Phenotypes with a Conventional Treatment Regimen in the Treatment of Patients with Active Takayasu's Arteritis
NCT05151848	ADATOFTAK	P4	unknown	Comparison of Adalimumab and Tofacitinib in the Treatment of Active Takayasu Arteritis
NCT05102448	—	P4	recruiting	Comparison of Tofacitinib and Methotrexate in Takayasu's Arteritis
NCT05749666	TOFGCTAK	P3	unknown	Comparison of Tofacitinib and Prednisolone in the Treatment of Active Takayasu's Arteritis
NCT04299971	—	P4	unknown	Efficiency of Methotrexate and Tofacitinib in Mild and Moderate Patients

Psoriasis (3)

NCT	Acronym	Phase	Status	Title
NCT07352566	—	P4	not yet recruiting	Utilization of a Microdevice for Psoriasis and Atopic Dermatitis
NCT07261306	MTX	Early P1	recruiting	Comparison Between Oral Methotrexate and Tofacitinib in Chronic Plaque Psoriasis
NCT01736696	—	P1	completed	Multiple Dose Escalation Study In Medically Stable Subjects With Psoriasis

Axial Spondyloarthritis (3)

NCT	Acronym	Phase	Status	Title
NCT06112665	FASTLANE	P4	recruiting	ToFAcitinib in Early Active Axial SpondyloarThritis:
NCT06310057	—	P4	completed	Tofacitinib in the Treatment of Refractory Axial Spondyloarthritis Patients: A Dose Escalation Study
NCT03738956	—	P2/P3	unknown	Safety and Efficacy of Tofacitinib in the Treatment of NSAID Refractory Axial Spondyloarthritis:A Clinical Trial

COVID-19 (3)

NCT	Acronym	Phase	Status	Title
NCT05638932	—	N/A	completed	Methodologies for Observational Studies Comparing Inpatient COVID-19 Treatments
NCT04412252	—	P2	withdrawn	Safety and Efficacy of Tofacitinib in Hospitalized Participants With COVID-19 Pneumonia Who Are Receiving Standard of Care Therapy
NCT04750317	TOFA-COV-2	P2	completed	Efficacy and Safety of Tofacitinib in Patients With COVID-19 Pneumonia

Sjogren's Syndrome (2)

NCT	Acronym	Phase	Status	Title
NCT07281456	—	P2	recruiting	Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren Disease
NCT04496960	—	P1/P2	active not recruiting	Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren's Syndrome

Granulomatosis With Polyangiitis (2)

NCT	Acronym	Phase	Status	Title
NCT04871191	SATELITE	P3	recruiting	Study of Salvage Therapy to Treat Patients With Granulomatosis With Polyangiitis
NCT04944524	—	P4	unknown	Comparison of Tofacitinib and Methotrexate in the Maintained Treatment of GPA

Atopic Dermatitis (AD) (2)

NCT	Acronym	Phase	Status	Title
NCT06810050	—	P2	completed	Phase 2b Safety and Efficacy Study of CGB-500 Topical Ointment With 0.5% and 1% Tofacitnib for Treatment of Atopic Dermatitis
NCT06923228	—	P2	completed	A Study to Assess Efficacy and Safety of CGB-500, 1% Tofacitinib Versus an Active Comparator for Atopic Dermatitis

Atopic Dermatitis (2)

NCT	Acronym	Phase	Status	Title
NCT06465732	—	P4	not yet recruiting	Efficacy and Safety of Dupilumab in Combination With Tofacitinib in Moderate to Severe Adult AD Patients
NCT05487963	—	P1/P2	completed	Tolerability and Effectiveness of CGB-500 Topical Ointment, 1% Tofacitinib, for the Treatment of Atopic Dermatitis

Dermatomyositis (2)

NCT	Acronym	Phase	Status	Title
NCT06438679	—	P4	enrolling by invitation	3T Therapy in the Treatment of MDA5-positive Dermatomyositis
NCT03002649	STIR	P1	completed	Study of Tofacitinib in Refractory Dermatomyositis

Polymyalgia Rheumatica (2)

NCT	Acronym	Phase	Status	Title
NCT06172361	ITTGPMR	P3	recruiting	Induction and Tapering Therapy With Tofacitinib and Glucocorticoid in Patients With Polymyalgia Rheumatica
NCT04799262	—	P2	completed	Tofacitinib as a GC Sparing Agent for Polymyalgia Rheumatica

Down Syndrome (2)

NCT	Acronym	Phase	Status	Title
NCT05662228	—	P2	active not recruiting	Therapies for Down Syndrome Regression Disorder
NCT04246372	—	P2	completed	Tofacitinib for Immune Skin Conditions in Down Syndrome

Cutaneous Lupus (2)

NCT	Acronym	Phase	Status	Title
NCT05048238	—	P1	completed	Evaluation of Tofacitinib in Prevention of Photosensitivity in Lupus
NCT03288324	—	P1/P2	completed	Open-label Study of Tofacitinib for Moderate to Severe Skin Involvement in Young Adults With Lupus

Ankylosing Spondylitis (2)

NCT	Acronym	Phase	Status	Title
NCT03502616	AS	P3	completed	Efficacy and Safety of Tofacitinib in Subjects With Active Ankylosing Spondylitis (AS)
NCT01786668	—	P2	completed	Dose-Ranging Study Of Tofacitinib In Adults With Active Ankylosing Spondylitis

Juvenile Idiopathic Arthritis (2)

NCT	Acronym	Phase	Status	Title
NCT01500551	—	P2/P3	completed	Long-Term Safety Study Of Tofacitinib In Patients With Juvenile Idiopathic Arthritis
NCT02592434	—	P3	completed	Efficacy Study Of Tofacitinib In Pediatric JIA Population

Psoriasis Vulgaris (2)

NCT	Acronym	Phase	Status	Title
NCT02193815	—	P1	completed	A 12 Day Study To Evaluate A Topical Drug To Treat Plaque Psoriasis
NCT01831466	—	P2	completed	Tofacitinib Ointment For Chronic Plaque Psoriasis

LAL (1)

NCT	Acronym	Phase	Status	Title
NCT07522801	ALL-TARGET	P2	not yet recruiting	A Precision Medicine Trial for Patients With Relapsed or Refractory T Cell ALL

Vitiligo, Generalized (1)

NCT	Acronym	Phase	Status	Title
NCT07055529	(PUVA)	Early P1	not yet recruiting	Comparison of Efficacy and Safety Psoralen Combined With Ultraviolet A (PUVA) Vs Tofacitinib in the Treatment of Generalized Vitiligo.

Thyroid Eye Disease, TED (1)

NCT	Acronym	Phase	Status	Title
NCT07547930	TOFA-GO	P2	recruiting	Tofacitinib for Glucocorticoid-Resistant Moderate-to-Severe Thyroid Eye Disease

Palmoplantar Pustulosis (PPP) (1)

NCT	Acronym	Phase	Status	Title
NCT07530367	—	P3	not yet recruiting	A Phase III Randomized Controlled Trial Evaluating the Efficacy and Safety of Tofacitinib Combined With Imatinib in Patients With Moderate-to-Severe Palmoplantar Pustulosis

Nail Psoriasis (1)

NCT	Acronym	Phase	Status	Title
NCT07313072	—	P2	not yet recruiting	Topical Use of 2% Tofacitinib for Nail Psoriasis: an Exploratory Clinical Study

Erythematotelangiectatic Rosacea (1)

NCT	Acronym	Phase	Status	Title
NCT07343635	—	N/A	recruiting	The Efficacy and Safety of Anti-inflammation Treatment (Hirudoid Introduction Followed by Yellow Light Therapy) Combined With Tofacitinib and Doxycycline in Chinese Adult Patients With Mild to Moderate Erythematous Telangiectatic Rosacea

Polyarticular Course Juvenile Idiopathic Arthritis (JIA) (1)

NCT	Acronym	Phase	Status	Title
NCT06654882	SMART-JIA	P3	recruiting	Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis

Inflamatory Bowel Disease (1)

NCT	Acronym	Phase	Status	Title
NCT07487311	GUS	N/A	recruiting	A Prospective Cohort Study Evaluating the Efficacy and Safety of Guselkumab (GUS) With JAK Inhibitors in Patients With Difficult-To-Treat Inflammatory Bowel Disease (IBD)

Acute Severe Ulcerative Colitis (1)

NCT	Acronym	Phase	Status	Title
NCT07297069	—	P2	not yet recruiting	Combination Therapy With Infliximab and Tofacitinib for Acute Severe Ulcerative Colitis - CINTO Trial

Juvenile Idiopathic Arthritis (JIA) (1)

NCT	Acronym	Phase	Status	Title
NCT07211932	—	N/A	not yet recruiting	Tofacitinib in Juvenile Idiopathic Arthritis

Oral Lichen Planus (1)

NCT	Acronym	Phase	Status	Title
NCT07131813	—	P4	recruiting	Evaluation of Efficacy and Safety of add-on Tofacitinib in Patients With Oral Lichen Planus

Rheumatic Disease (1)

NCT	Acronym	Phase	Status	Title
NCT07138898	—	P2	not yet recruiting	Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty

Rheumatoid Arthritis (RA (1)

NCT	Acronym	Phase	Status	Title
NCT06945666	—	P4	not yet recruiting	A Study of Iguratimod in Combination With Tofacitinib in RA Patients

Telitacicept (1)

NCT	Acronym	Phase	Status	Title
NCT06979271	—	N/A	recruiting	Efficacy and Safety of Telitacicept Combined With Tofacitinib for Refractory Rheumatoid Arthritis

Moderate to Severe Rheumatoid Arthritis (1)

NCT	Acronym	Phase	Status	Title
NCT07008846	—	P3	active not recruiting	Efficacy of Tofacitinib, Methotrexate Combination Therapy Versus Upadacitinib, Methotrexate Combination Therapy in Moderate to Severe Rheumatoid Arthritis

Cutaneous T-Cell Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT06698822	CTCL	P2	recruiting	A Phase 2 Trial to Assess Safety and Efficacy of Tofacitinib 2% Cream in the Treatment of Cutaneous T-cell Lymphoma (CTCL), Stages IA, IB, and IIA

Primary Cutaneous Amyloidosis (1)

NCT	Acronym	Phase	Status	Title
NCT06998875	—	P4	recruiting	A Prospective Cohort Study on Primary Cutaneous Amyloidosis

Vitiligo (1)

NCT	Acronym	Phase	Status	Title
NCT07044141	NB-UVB	P1	active not recruiting	Efficacy of Oral Tofacitinib in Combination of Narrow Band UVB in Treatment of Vitiligo

Rhumatoid Arthisis (1)

NCT	Acronym	Phase	Status	Title
NCT06687551	JAK-TAP	P4	not yet recruiting	JAK Inhibitor Dose TAPering Strategy Study

Scleroderma, Systemic (1)

NCT	Acronym	Phase	Status	Title
NCT07472166	—	P4	completed	Efficacy of Tofacitinib on Skin Thickening in Diffuse Cutaneous Systemic Sclerosis: A Comparative Study With Methotrexate

Hidradenitis Suppurativa (1)

NCT	Acronym	Phase	Status	Title
NCT06707246	—	N/A	recruiting	A Randomized Trial Comparing the Efficacy and Safety of Secukinumab with Tofacitinib in the Treatment of Moderate to Severe Hidradenitis Suppurativa in Chinese Patients

Amyotrophic Lateral Sclerosis (1)

NCT	Acronym	Phase	Status	Title
NCT06689982	TALENT	Early P1	not yet recruiting	Tofacitinib in Patients With Amyotrophic Lateral Sclerosis

Glucocorticoid Resistant ICIs-related Myocarditis (1)

NCT	Acronym	Phase	Status	Title
NCT06393972	—	P2	not yet recruiting	The Efficacy and Safety of Tofacitinib in Patients With Glucocorticoid Resistant ICIs-related Myocarditis

Prurigo Nodularis (1)

NCT	Acronym	Phase	Status	Title
NCT06201715	—	N/A	unknown	Efficacy and Safety of Tofacitinib in Patients With Prurigo Nodularis

Efficacy of Tofacitinib in the Systemic Sclerosis (1)

NCT	Acronym	Phase	Status	Title
NCT06044844	—	P2	unknown	Effectiveness of Tofacitinib in Systemic Sclerosis

Frontal Fibrosing Alopecia (1)

NCT	Acronym	Phase	Status	Title
NCT06202560	Tofacitinib	N/A	completed	Effectiveness and Safety of Tofacitinib in Patients With Recalcitrant Frontal Fibrosing Alopecia : A Pilot Study

Spondyloarthritis, Axial (1)

NCT	Acronym	Phase	Status	Title
NCT06114407	—	P2	unknown	Baricitinib in the Treatment of Refractory Axial Spondyloarthritis Patients: A Comparison With Tofacitinib

Cutaneous Leishmaniasis, American (1)

NCT	Acronym	Phase	Status	Title
NCT06011343	CLTofa23	P2/P3	unknown	Tofacitinib Associated With Meglumine Antimoniate in Cutaneous Leishmaniasis

Toxic Epidermal Necrolysis (1)

NCT	Acronym	Phase	Status	Title
NCT06119490	TEN	Early P1	recruiting	Evaluation of the Efficacy and Safety of Methylprednisolone Combined With the JAK Inhibitors in the Treatment of Toxic Epidermal Necrolysis

Aneurysm (1)

NCT	Acronym	Phase	Status	Title
NCT05845723	—	P2	recruiting	Tocilizumab and Tofacitinib in the Treatment of Vascular Behçet's Syndrome

Active Ankylosing Spondylitis (1)

NCT	Acronym	Phase	Status	Title
NCT05814939	—	P2	completed	Efficacy and Safety Clinical Study of VC005 Tablets in Subjects With Active Ankylosing Spondylitis.

IgG4-related Disease (1)

NCT	Acronym	Phase	Status	Title
NCT05625581	—	N/A	unknown	Tofatib Treatment for IgG4-related Disease

Glioblastoma (1)

NCT	Acronym	Phase	Status	Title
NCT05326464	—	P3	active not recruiting	Tofacitinib in Recurrent GBM Patients

Chronic Granulomatous Disease (1)

NCT	Acronym	Phase	Status	Title
NCT05104723	—	P1/P2	completed	Safety and Efficacy of Tofacitinib for Chronic Granulomatous Disease With Inflammatory Complications

Extensive Alopecia Areata (1)

NCT	Acronym	Phase	Status	Title
NCT06157905	—	Early P1	completed	Efficacy and Safety of Oral Tofacitinib in the Treatment of Alopecia Areata

Stevens-Johnson Syndrome (1)

NCT	Acronym	Phase	Status	Title
NCT06474078	—	N/A	completed	Study To Evaluate The Efficacy Of Tofacitinib In Patients With SJS/TEN

Idiopathic Inflammatory Myopathies (1)

NCT	Acronym	Phase	Status	Title
NCT05400889	—	P2	unknown	Clinical Characteristics and Mechanism Research of Inhibitors of Janus Kinase in the Idiopathic Inflammatory Myopathies

Diffuse Large B Cell Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT05348213	R-ICE+X	P2	recruiting	Novel Targeted Drugs Combined With R-ICE Regimen in Relapsed and Refractory Diffuse Large B-cell Lymphoma

Immune-Mediated Colitis (1)

NCT	Acronym	Phase	Status	Title
NCT04768504	—	P2	terminated	Tofacitinib for the Treatment of Refractory Immune-related Colitis from Checkpoint Inhibitor Therapy- TRICK Study

Active Moderate to Severe Rheumatoid Arthritis (1)

NCT	Acronym	Phase	Status	Title
NCT04876781	XRPMS	N/A	recruiting	Korean Post-marketing Surveillance for Xeljanz XR

Primary Sjögren's Syndrome (1)

NCT	Acronym	Phase	Status	Title
NCT05087589	—	P2	unknown	Efficacy, Safety and Immunological Evaluation of Tofacitinib in the Treatment of Primary Sjogren's Syndrome

Ulcerative Colitis Acute (1)

NCT	Acronym	Phase	Status	Title
NCT04925973	TRIUMPH	P2	active not recruiting	Tofacitinib for Hospitalized Acute Severe Ulcerative Colitis Management

Pouchitis (1)

NCT	Acronym	Phase	Status	Title
NCT04580277	—	P2	terminated	Tofacitinib For Treatment Of Chronic Pouchitis

Arthritis Rheumatoid (1)

NCT	Acronym	Phase	Status	Title
NCT04721821	—	N/A	completed	Comparative Effectiveness Of Tumor Necrosis Factor Inhibitors And Tofacitinib Use In Earlier Lines Of Therapy And Use As Monotherapy.

Healthy Subjects (1)

NCT	Acronym	Phase	Status	Title
NCT04468425	—	P1	completed	Tofacitinib Citrate Topical Gel 3.2% FDA BA Bridging Study

COVID-19 Pneumonia (1)

NCT	Acronym	Phase	Status	Title
NCT04415151	I-TOMIC	P2	terminated	Tofacitinib for Treatment of Moderate COVID-19

Clinically Amyopathic Dermatomyisitis(CAMD) (1)

NCT	Acronym	Phase	Status	Title
NCT04613219	—	N/A	unknown	Correlation Between the Change of Peripheral Lymphocyte Subsets and Clinically Amyopathic Dermatomyositis Combined With Rapidly Progressive Interstitial Lung Disease

Covid19 (1)

NCT	Acronym	Phase	Status	Title
NCT04469114	—	P3	completed	Tofacitinib in Hospitalized Patients With COVID-19 Pneumonia

Alopecia Totalis/Universalis (1)

NCT	Acronym	Phase	Status	Title
NCT07101471	—	N/A	completed	Rhofanib® (Tofacitinib) Safety and Effectiveness Evaluation

Pneumonitis, Interstitial (1)

NCT	Acronym	Phase	Status	Title
NCT04390061	TOFACoV-2	P2	unknown	TOFAcitinib Plus Hydroxycloroquine vs Hydroxycloroquine in Patients With COVID-19 Interstitial Pneumonia

Myasthenia Gravis, Generalized (1)

NCT	Acronym	Phase	Status	Title
NCT04431895	—	Early P1	completed	Safety And Efficacy Of Tofacitinib In Patients With Refractory Myasthenia Gravis: A Pilot Study

SARS-COv2 Related Interstitial Pneumonia (1)

NCT	Acronym	Phase	Status	Title
NCT04332042	—	P2	unknown	TOFAcitinib in SARS-CoV2 Pneumonia

Depression (1)

NCT	Acronym	Phase	Status	Title
NCT04141904	TIDE	P1/P2	terminated	Tofacitinib in Depression (TIDE)

ANCA Associated Vasculitis (1)

NCT	Acronym	Phase	Status	Title
NCT04973033	—	N/A	completed	Effect of Tofacitinib in Treating ANCA-associated Vasculitis

Rheumatic Arthritis (1)

NCT	Acronym	Phase	Status	Title
NCT04485325	AcceleRAte	P4	completed	Capability of Tofacitinib or Etanercept to Accelerate Tapering of NSAID and Treat-to-target Guided De-escalation of Corticosteroids in RA Patients

Inflammatory Bowel Diseases (1)

NCT	Acronym	Phase	Status	Title
NCT03885713	BioIBD	P4	completed	Identification of Predictive Biomarkers for Response to Biologic Therapies and Tofacitinib in Inflammatory Bowel Disease

Diaphragm Injury (1)

NCT	Acronym	Phase	Status	Title
NCT03681275	—	P2	recruiting	Janus Kinase Inhibition to Prevent Ventilator-induced Diaphragm Dysfunction

Neoplasms With Mesothelin Expression (1)

NCT	Acronym	Phase	Status	Title
NCT04034238	—	P1	completed	Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors

Sarcoidosis, Pulmonary (1)

NCT	Acronym	Phase	Status	Title
NCT03793439	—	P1	completed	Tofacitinib Hypothesis-generating, Pilot Study for Corticosteroid-Dependent Sarcoidosis

Cutaneous Sarcoidosis (1)

NCT	Acronym	Phase	Status	Title
NCT03910543	—	P1	completed	Open-label Trial of Tofacitinib in Cutaneous Sarcoidosis and Granuloma Annulare

Uveitis (1)

NCT	Acronym	Phase	Status	Title
NCT03580343	—	P2	unknown	Tofacitinib for Inflammatory Eye Disease

Extranodal NK/T-cell Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT03598959	—	P2	unknown	Tofacitinib Combined With Chidamide in R/R ENKTCL

Arthritis Juvenile Idiopathic (1)

NCT	Acronym	Phase	Status	Title
NCT03000439	—	P3	completed	A Safety, Efficacy And Pharmacokinetics Study Of Tofacitinib In Pediatric Patients With sJIA

Spondyloarthritis (1)

NCT	Acronym	Phase	Status	Title
NCT03504072	—	P4	unknown	Risk of Tuberculous and Other Infections in Patients of Spondyloarthritis Treated With Tofacitinib in Bangladesh

Systemic Sclerosis (1)

NCT	Acronym	Phase	Status	Title
NCT03274076	TOFA-SSc	P1/P2	completed	Evaluation of Tofacitinib in Early Diffuse Cutaneous Systemic Sclerosis (dcSSc)

Active Mild Ulcerative Colitis, Active Moderate Ulcerative Colitis, Healthy Subjects (1)

NCT	Acronym	Phase	Status	Title
NCT03103412	UC	P1	completed	TD-3504 SAD in Healthy Subjects and Subjects With Ulcerative Colitis (UC)

Discoid Lupus Erythematosus (1)

NCT	Acronym	Phase	Status	Title
NCT03159936	DLE	Early P1	terminated	Oral Tofacitinib in Adult Subjects With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE)

Blau Syndrome (1)

NCT	Acronym	Phase	Status	Title
NCT06688838	inapplicable	N/A	enrolling by invitation	Effective Treatment of Jak1/3 Inhibitor in Blau Syndrome

Systemic Lupus Erythematosus (1)

NCT	Acronym	Phase	Status	Title
NCT02535689	—	P1	completed	Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Systemic Lupus Erythematosus

Rhematoid Arthritis (1)

NCT	Acronym	Phase	Status	Title
NCT02187055	ORAL STRATEGY	P4	completed	An Efficacy And Safety Study Evaluating Tofacitinib With And Without Methotrexate Compared To Adalimumab With Methotrexate

Alopecia Areata (AA) (1)

NCT	Acronym	Phase	Status	Title
NCT02197455	—	P2	completed	Tofacitnib for the Treatment of Alopecia Areata and Variants

Arthritis, Psoriatic (1)

NCT	Acronym	Phase	Status	Title
NCT01976364	OPAL BALANCE	P3	completed	Open-Label Extension Study Of Tofacitinib In Psoriatic Arthritis

Dermatitis, Atopic (1)

NCT	Acronym	Phase	Status	Title
NCT02001181	—	P2	completed	Tofacitinib Ointment For Atopic Dermatitis (Atopic Eczema)

Plaque Psoriasis (1)

NCT	Acronym	Phase	Status	Title
NCT01710046	—	P2	completed	Study Of The Mechanism Of Action Of CP-690,550 In The Skin Of Subjects With Moderate To Severe Chronic Plaque Psoriasis

Kidney Transplantation (1)

NCT	Acronym	Phase	Status	Title
NCT01375127	—	N/A	completed	Collection of Follow-up Data From CP-690,550-treated Kidney Transplant Recipients

Tofacitinib pivotal trial highlights (Phase 2/3/4)

Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.

Acronym	NCT	Phase	Status	Indication	Enrollment	PubMed
JAK-TAP	NCT06687551	P4	not yet recruiting	Rhumatoid Arthisis	308	—
UC	NCT06095128	P4	recruiting	Ulcerative Colitis	65	—
TOFSTAT	NCT07554820	P4	recruiting	Rheumatoid Arthritis	120	—
TOFA-MTX-AA	NCT07406204	P4	not yet recruiting	Alopecia Areata	78	—
FASTLANE	NCT06112665	P4	recruiting	Axial Spondyloarthritis	104	PMID 40078463
ADATOFTAK	NCT05151848	P4	unknown	Takayasu Arteritis	100	—
RA	NCT03976245	P4	recruiting	Rheumatoid Arthritis	144	—
BioIBD	NCT03885713	P4	completed	Inflammatory Bowel Diseases	180	PMID 26353983
COVER	NCT05080218	P4	completed	Rheumatoid Arthritis	841	—
AcceleRAte	NCT04485325	P4	completed	Rheumatic Arthritis	92	—
PULMORA	NCT04311567	P4	terminated	Rheumatoid Arthritis	3	—
TF	NCT04928066	P4	completed	Arthritis, Rheumatoid	100	—
TNF	NCT02092467	P4	completed	Arthritis, Rheumatoid	4,372	PMID 35081280
ORAL STRATEGY	NCT02187055	P4	completed	Rhematoid Arthritis	1,152	PMID 38958913
SATELITE	NCT04871191	P3	recruiting	Granulomatosis With Polyangiitis	42	PMID 27338776
SMART-JIA	NCT06654882	P3	recruiting	Polyarticular Course Juvenile Idiopathic Arthritis (JIA)	400	—
TARA	NCT06020144	P3	active not recruiting	Rheumatoid Arthritis	459	—
ITTGPMR	NCT06172361	P3	recruiting	Polymyalgia Rheumatica	98	PMID 37730835
TOFGCTAK	NCT05749666	P3	unknown	Takayasu Arteritis	50	—
contRAst 2	NCT03970837	P3	terminated	Arthritis, Rheumatoid	1,764	PMID 37699654
contRAst 1	NCT03980483	P3	completed	Arthritis, Rheumatoid	1,537	—
AS	NCT03502616	P3	completed	Ankylosing Spondylitis	270	PMID 41039829
PsOLSET-BD	NCT03736161	P3	completed	Psoriatic Arthritis	61	PMID 28130206
OPAL BALANCE	NCT01976364	P3	completed	Arthritis, Psoriatic	686	PMID 38273637
LDA	NCT02566967	P3	completed	Rheumatoid Arthritis	20	—
OPAL BEYOND	NCT01882439	P3	completed	Psoriatic Arthritis	395	PMID 34870800
OPAL BROADEN	NCT01877668	P3	completed	Psoriatic Arthritis	422	PMID 36526796
OCTAVE	NCT01458951	P3	completed	Ulcerative Colitis	547	PMID 35648151
OCTAVE	NCT01465763	P3	completed	Ulcerative Colitis	614	PMID 33513294
ALL-TARGET	NCT07522801	P2	not yet recruiting	LAL	93	—
TOFA-GO	NCT07547930	P2	recruiting	Thyroid Eye Disease, TED	8	PMID 40324443
CTCL	NCT06698822	P2	recruiting	Cutaneous T-Cell Lymphoma	20	—
R-ICE+X	NCT05348213	P2	recruiting	Diffuse Large B Cell Lymphoma	76	—
RAILDTo	NCT05246293	P2	unknown	Rheumatoid Arthritis	60	PMID 33976699
TRIUMPH	NCT04925973	P2	active not recruiting	Ulcerative Colitis Acute	24	PMID 40092634
PASTOR	NCT04062695	P2	unknown	Psoriatic Arthritis	80	PMID 34785545
I-TOMIC	NCT04415151	P2	terminated	COVID-19 Pneumonia	24	—
TOFACoV-2	NCT04390061	P2	unknown	Pneumonitis, Interstitial	116	—
TOFA-COV-2	NCT04750317	P2	completed	COVID-19	414	—
MRI	NCT01164579	P2	completed	Rheumatoid Arthritis	109	PMID 33057725

Terminated and withdrawn Tofacitinib trials (9)

Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.

NCT04311567terminatedEffects of Tofacitinib vs Methotrexate on Rheumatoid Arthritis Interstitial Lung Disease
NCT04768504terminatedTofacitinib for the Treatment of Refractory Immune-related Colitis from Checkpoint Inhibitor Therapy- TRICK Study
NCT04580277terminatedTofacitinib For Treatment Of Chronic Pouchitis
NCT05165771withdrawnStudy to Evaluate Safety, Tolerability, and Efficacy of GS-5718 in Participants With Active Rheumatoid Arthritis Who Have an Inadequate Response to Disease-modifying Antirheumatic Drug(s) (bDMARDs) Treatment
NCT03970837terminatedEfficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic (cs)/Biologic (b) Disease Modifying Anti-rheumatic Drugs (DMARDs)
NCT04141904terminatedTofacitinib in Depression (TIDE)
NCT04415151terminatedTofacitinib for Treatment of Moderate COVID-19
NCT04412252withdrawnSafety and Efficacy of Tofacitinib in Hospitalized Participants With COVID-19 Pneumonia Who Are Receiving Standard of Care Therapy
NCT03159936terminatedOral Tofacitinib in Adult Subjects With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE)

All Tofacitinib trials (189)

Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.

NCT ID	Acronym	Title	Phase	Status	Enrollment	Sponsor	Started
NCT07281456		Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren Disease	P2	recruiting	60	National Institute of Dental and Craniofacial Research (NIDCR)	Dec 2025
NCT07352566		Utilization of a Microdevice for Psoriasis and Atopic Dermatitis	P4	not yet recruiting	10	University of California, San Francisco	Aug 2026
NCT07522801	ALL-TARGET	A Precision Medicine Trial for Patients With Relapsed or Refractory T Cell ALL	P2	not yet recruiting	93	Philippe ROUSSELOT	Sep 2026
NCT06301373		Methotrexate Combined With Tofacitinib in Rheumatoid Arthritis	N/A	recruiting	130	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	Sep 2024
NCT04624230		Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis	P3	active not recruiting	118	Pfizer	Aug 2021
NCT06687551	JAK-TAP	JAK Inhibitor Dose TAPering Strategy Study	P4	not yet recruiting	308	University Hospital, Toulouse	Jan 2025
NCT04871191	SATELITE	Study of Salvage Therapy to Treat Patients With Granulomatosis With Polyangiitis	P3	recruiting	42	Assistance Publique - Hôpitaux de Paris	Jun 2025
NCT03414502		Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response	P3	recruiting	400	University of Nebraska	Dec 2007
NCT07487311	GUS	A Prospective Cohort Study Evaluating the Efficacy and Safety of Guselkumab (GUS) With JAK Inhibitors in Patients With Difficult-To-Treat Inflammatory Bowel Disease (IBD)	—	recruiting	80	Second Affiliated Hospital, School of Medicine, Zhejiang University	Jan 2026
NCT07530367		A Phase III Randomized Controlled Trial Evaluating the Efficacy and Safety of Tofacitinib Combined With Imatinib in Patients With Moderate-to-Severe Palmoplantar Pustulosis	P3	not yet recruiting	135	Second Affiliated Hospital, School of Medicine, Zhejiang University	Apr 2026
NCT07297069		Combination Therapy With Infliximab and Tofacitinib for Acute Severe Ulcerative Colitis - CINTO Trial	P2	not yet recruiting	60	Asian Institute of Gastroenterology, India	Jan 2026
NCT07547930	TOFA-GO	Tofacitinib for Glucocorticoid-Resistant Moderate-to-Severe Thyroid Eye Disease	P2	recruiting	8	The First Affiliated Hospital of Xiamen University	Apr 2026
NCT07406035		A Phase II Clinical Trial to Evaluate the Efficacy and Safety of TQH3906 Capsules in the Treatment of Active Psoriatic Arthritis	P2	not yet recruiting	156	Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.	Apr 2026
NCT06707246		A Randomized Trial Comparing the Efficacy and Safety of Secukinumab with Tofacitinib in the Treatment of Moderate to Severe Hidradenitis Suppurativa in Chinese Patients	N/A	recruiting	60	Second Affiliated Hospital, School of Medicine, Zhejiang University	Dec 2024
NCT07138898		Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty	P2	not yet recruiting	80	NYU Langone Health	Sep 2025
NCT06095128	UC	A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)	P4	recruiting	65	Takeda	Jun 2024
NCT07343635		The Efficacy and Safety of Anti-inflammation Treatment (Hirudoid Introduction Followed by Yellow Light Therapy) Combined With Tofacitinib and Doxycycline in Chinese Adult Patients With Mild to Moderate Erythematous Telangiectatic Rosacea	N/A	recruiting	186	The Fourth Affiliated Hospital of Zhejiang University School of Medicine	Feb 2026
NCT06498089		A Randomized, Controlled, Open-label, Multicenter Clinical Trial Comparing the Efficacy and Safety of a Precision Treatment Regimen Based on Clinical-molecular Phenotypes with a Conventional Treatment Regimen in the Treatment of Patients with Active Takayasu's Arteritis	P4	recruiting	124	Shanghai Zhongshan Hospital	Jun 2024
NCT07131813		Evaluation of Efficacy and Safety of add-on Tofacitinib in Patients With Oral Lichen Planus	P4	recruiting	60	All India Institute of Medical Sciences, Bhubaneswar	Oct 2025
NCT05845723		Tocilizumab and Tofacitinib in the Treatment of Vascular Behçet's Syndrome	P2	recruiting	81	Peking Union Medical College Hospital	Jun 2023
NCT05326464		Tofacitinib in Recurrent GBM Patients	P3	active not recruiting	17	University of Texas Southwestern Medical Center	Oct 2022
NCT06945666		A Study of Iguratimod in Combination With Tofacitinib in RA Patients	P4	not yet recruiting	200	Jie Chang	Aug 2025
NCT06979271		Efficacy and Safety of Telitacicept Combined With Tofacitinib for Refractory Rheumatoid Arthritis	—	recruiting	20	Zhejiang Provincial People's Hospital	Jun 2025
NCT07313072		Topical Use of 2% Tofacitinib for Nail Psoriasis: an Exploratory Clinical Study	P2	not yet recruiting	10	Hexsel Dermatology Clinic	Mar 2026
NCT07055529	(PUVA)	Comparison of Efficacy and Safety Psoralen Combined With Ultraviolet A (PUVA) Vs Tofacitinib in the Treatment of Generalized Vitiligo.	Early P1	not yet recruiting	64	Hayat Abad Medical Complex, Peshawar	Jun 2026
NCT06654882	SMART-JIA	Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis	P3	recruiting	400	Duke University	Jan 2026
NCT07211932		Tofacitinib in Juvenile Idiopathic Arthritis	—	not yet recruiting	58	Consorci Sanitari de l'Alt Penedès i Garraf	Dec 2025
NCT06573593		Efficacy and Safety of JAK Inhibitors in Patients With AA: RWE Study	—	recruiting	150	Second Affiliated Hospital, School of Medicine, Zhejiang University	Jul 2024
NCT06438679		3T Therapy in the Treatment of MDA5-positive Dermatomyositis	P4	enrolling by invitation	133	Second Affiliated Hospital, School of Medicine, Zhejiang University	Mar 2024
NCT06020144	TARA	A Phase 3 Study Comparing TLL-018 to Tofacitinib in RA Subjects With Inadequate Response or Intolerance to bDMARDs	P3	active not recruiting	459	Hangzhou Highlightll Pharmaceutical Co., Ltd	Nov 2023
NCT05662228		Therapies for Down Syndrome Regression Disorder	P2	active not recruiting	66	University of Colorado, Denver	Jun 2023
NCT05186623		Prediction Model for Response to Biologics and Small Molecular Agent for UC	—	recruiting	300	Asan Medical Center	Feb 2022
NCT06688838	inapplicable	Effective Treatment of Jak1/3 Inhibitor in Blau Syndrome	—	enrolling by invitation	24	Tongji Hospital	Jan 2017
NCT06393972		The Efficacy and Safety of Tofacitinib in Patients With Glucocorticoid Resistant ICIs-related Myocarditis	P2	not yet recruiting	25	Shanghai Zhongshan Hospital	Jul 2024
NCT03681275		Janus Kinase Inhibition to Prevent Ventilator-induced Diaphragm Dysfunction	P2	recruiting	70	Stanford University	Sep 2019
NCT06698822	CTCL	A Phase 2 Trial to Assess Safety and Efficacy of Tofacitinib 2% Cream in the Treatment of Cutaneous T-cell Lymphoma (CTCL), Stages IA, IB, and IIA	P2	recruiting	20	M.D. Anderson Cancer Center	Mar 2025
NCT07554820	TOFSTAT	Major Adverse Cardiovascular Events (MACE) in Rheumatoid Arthritis Patient With Moderate to Severe Disease Activity Treated With Tofacitinib and Statins vs TNF Inhibitors: TOFSTAT CLINICAL TRIAL	P4	recruiting	120	Shaikh Zayed Hospital, Lahore	Dec 2025
NCT07008846		Efficacy of Tofacitinib, Methotrexate Combination Therapy Versus Upadacitinib, Methotrexate Combination Therapy in Moderate to Severe Rheumatoid Arthritis	P3	active not recruiting	96	Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh	May 2025
NCT06119490	TEN	Evaluation of the Efficacy and Safety of Methylprednisolone Combined With the JAK Inhibitors in the Treatment of Toxic Epidermal Necrolysis	Early P1	recruiting	30	Peng Zhang	Jul 2023
NCT04496960		Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren's Syndrome	P1/P2	active not recruiting	23	National Institute of Dental and Craniofacial Research (NIDCR)	May 2021
NCT06176508		Efficacy and Safety of HS-10374 Compared to Placebo in Adults With Active Psoriatic Arthritis	P2	recruiting	160	Hansoh BioMedical R&D Company	Feb 2024
NCT07406204	TOFA-MTX-AA	Tofacitinib vs Methotrexate for Severe Alopecia Areata (TOFA-MTX-AA)	P4	not yet recruiting	78	Hayat Abad Medical Complex, Peshawar	Feb 2026
NCT06465732		Efficacy and Safety of Dupilumab in Combination With Tofacitinib in Moderate to Severe Adult AD Patients	P4	not yet recruiting	220	Second Affiliated Hospital, School of Medicine, Zhejiang University	Jan 2025
NCT06112665	FASTLANE	ToFAcitinib in Early Active Axial SpondyloarThritis:	P4	recruiting	104	Charite University, Berlin, Germany	Nov 2023
NCT04876781	XRPMS	Korean Post-marketing Surveillance for Xeljanz XR	—	recruiting	200	Pfizer	Jan 2022
NCT06689982	TALENT	Tofacitinib in Patients With Amyotrophic Lateral Sclerosis	Early P1	not yet recruiting	12	Beijing Tiantan Hospital	Dec 2024
NCT05112263	TOCASU	Tofacitinib Versus Cyclosporine for Steroid Refractory Acute Severe Ulcerative Colitis	N/A	unknown	96	Post Graduate Institute of Medical Education and Research, Chandigarh	Jul 2023
NCT05104723		Safety and Efficacy of Tofacitinib for Chronic Granulomatous Disease With Inflammatory Complications	P1/P2	completed	10	National Institute of Allergy and Infectious Diseases (NIAID)	Aug 2022
NCT06625450		TOFACITINIB vs TOFACITINIB WITH MESALAMINE IN ULCERATIVE COLITIS	P4	not yet recruiting	75	Post Graduate Institute of Medical Education and Research, Chandigarh	Oct 2024
NCT06172361	ITTGPMR	Induction and Tapering Therapy With Tofacitinib and Glucocorticoid in Patients With Polymyalgia Rheumatica	P3	recruiting	98	Zhejiang University	Jan 2024
NCT05151848	ADATOFTAK	Comparison of Adalimumab and Tofacitinib in the Treatment of Active Takayasu Arteritis	P4	unknown	100	Chinese SLE Treatment And Research Group	Jan 2022
NCT06998875		A Prospective Cohort Study on Primary Cutaneous Amyloidosis	P4	recruiting	56	Army Medical University, China	Mar 2025
NCT05625581		Tofatib Treatment for IgG4-related Disease	—	unknown	40	Changhai Hospital	Nov 2022
NCT05313620		Effect of Tofacitinib on Coagulation and Platelet Function, and Its Role in Thromboembolic Events	P4	recruiting	30	Fundación de Investigación Biomédica - Hospital Universitario de La Princesa	Apr 2022
NCT05102448		Comparison of Tofacitinib and Methotrexate in Takayasu's Arteritis	P4	recruiting	76	Shanghai Zhongshan Hospital	Nov 2021
NCT06201715		Efficacy and Safety of Tofacitinib in Patients With Prurigo Nodularis	N/A	unknown	24	Second Affiliated Hospital, School of Medicine, Zhejiang University	May 2024
NCT05803135		Iguratimod Combined With Tofacitinib in the Treatment of Rheumatoid Arthritis	P4	unknown	138	Nanfang Hospital, Southern Medical University	Mar 2023
NCT07261306	MTX	Comparison Between Oral Methotrexate and Tofacitinib in Chronic Plaque Psoriasis	Early P1	recruiting	75	Lahore General Hospital	Aug 2025
NCT04424303	TOFAST	Tofacitinib in Adult Patients With Moderate to Severe Ulcerative Colitis	—	completed	152	Pfizer	Dec 2020
NCT03755466		Examination of Efficacy and Safety of Baricitinib in RA Patients	P2	unknown	90	Shinshu University	Nov 2018
NCT06810050		Phase 2b Safety and Efficacy Study of CGB-500 Topical Ointment With 0.5% and 1% Tofacitnib for Treatment of Atopic Dermatitis	P2	completed	180	CAGE Bio Inc.	Dec 2024
NCT04610476		Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic Arthritis	P3	unknown	270	University of Erlangen-Nürnberg Medical School	Oct 2020
NCT06923228		A Study to Assess Efficacy and Safety of CGB-500, 1% Tofacitinib Versus an Active Comparator for Atopic Dermatitis	P2	completed	3	CAGE Bio Inc.	Apr 2025
NCT07044141	NB-UVB	Efficacy of Oral Tofacitinib in Combination of Narrow Band UVB in Treatment of Vitiligo	P1	active not recruiting	20	Lahore General Hospital	Mar 2025
NCT04338204	ODEN	Observational Study To Assess The Effectiveness and Treatment Adherence Of Tofacitinib of Ulcerative Colitis In Clinical Practice In Sweden	—	completed	102	Pfizer	Sep 2020
NCT07472166		Efficacy of Tofacitinib on Skin Thickening in Diffuse Cutaneous Systemic Sclerosis: A Comparative Study With Methotrexate	P4	completed	34	Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh	Dec 2024
NCT05749666	TOFGCTAK	Comparison of Tofacitinib and Prednisolone in the Treatment of Active Takayasu's Arteritis	P3	unknown	50	Chinese SLE Treatment And Research Group	Jan 2023
NCT06011343	CLTofa23	Tofacitinib Associated With Meglumine Antimoniate in Cutaneous Leishmaniasis	P2/P3	unknown	22	Hospital Universitário Professor Edgard Santos	Oct 2023
NCT06474078		Study To Evaluate The Efficacy Of Tofacitinib In Patients With SJS/TEN	N/A	completed	20	Chang Gung Memorial Hospital	Aug 2022
NCT07101471		Rhofanib® (Tofacitinib) Safety and Effectiveness Evaluation	—	completed	296	NanoAlvand	Aug 2020
NCT05348213	R-ICE+X	Novel Targeted Drugs Combined With R-ICE Regimen in Relapsed and Refractory Diffuse Large B-cell Lymphoma	P2	recruiting	76	Ruijin Hospital	May 2022
NCT03976245	RA	Advanced Therapeutics in Rheumatoid Arthritis (RA)	P4	recruiting	144	London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's	Mar 2020
NCT05246293	RAILDTo	Tofacitinib in the Treatment of Rheumatoid Arthritis-related Interstitial Lung Disease.	P2	unknown	60	National Institute of Respiratory Diseases, Mexico	Aug 2022
NCT01500551		Long-Term Safety Study Of Tofacitinib In Patients With Juvenile Idiopathic Arthritis	P2/P3	completed	302	Pfizer	Mar 2013
NCT03440892	SurviTreat	Effects of Antirheumatic Treatment on Levels of Survivin in Rheumatoid Arthritis Patients	—	unknown	2,500	Vastra Gotaland Region	Nov 2017
NCT05606107		To Compare the Efficacy and Safety of Low-dose Glucocorticoids and Tofacitinib in Alleviating Moderate to High Disease Activity Rheumatoid Arthritis for 24 Weeks	P4	unknown	230	Second Affiliated Hospital, School of Medicine, Zhejiang University	May 2022
NCT03885713	BioIBD	Identification of Predictive Biomarkers for Response to Biologic Therapies and Tofacitinib in Inflammatory Bowel Disease	P4	completed	180	Fundación de Investigación Biomédica - Hospital Universitario de La Princesa	Sep 2019
NCT06114407		Baricitinib in the Treatment of Refractory Axial Spondyloarthritis Patients: A Comparison With Tofacitinib	P2	unknown	184	Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh	Oct 2023
NCT04246372		Tofacitinib for Immune Skin Conditions in Down Syndrome	P2	completed	47	University of Colorado, Denver	Oct 2020
NCT04449224		Comparative Effectiveness of Targeted Therapy in RA Patients	—	unknown	506	Hanyang University	Apr 2020
NCT06418529		A Study to Understand How Effective is Tofacitinib When Compared to Other Advanced Treatments in Patients With Rheumatoid Arthritis	—	completed	21,340	Pfizer	May 2024
NCT06202560	Tofacitinib	Effectiveness and Safety of Tofacitinib in Patients With Recalcitrant Frontal Fibrosing Alopecia : A Pilot Study	N/A	completed	11	Institute of Dermatology, Thailand	Nov 2023
NCT04944524		Comparison of Tofacitinib and Methotrexate in the Maintained Treatment of GPA	P4	unknown	66	Shanghai Zhongshan Hospital	Jul 2021
NCT06044844		Effectiveness of Tofacitinib in Systemic Sclerosis	P2	unknown	44	Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh	Nov 2023
NCT05080218	COVER	COVID-19 VaccinE Response in Rheumatology Patients	P4	completed	841	Jeffrey Curtis	Nov 2021
NCT05814939		Efficacy and Safety Clinical Study of VC005 Tablets in Subjects With Active Ankylosing Spondylitis.	P2	completed	180	Jiangsu vcare pharmaceutical technology co., LTD	Apr 2023
NCT04431895		Safety And Efficacy Of Tofacitinib In Patients With Refractory Myasthenia Gravis: A Pilot Study	Early P1	completed	19	Huashan Hospital	Jun 2020
NCT04485325	AcceleRAte	Capability of Tofacitinib or Etanercept to Accelerate Tapering of NSAID and Treat-to-target Guided De-escalation of Corticosteroids in RA Patients	P4	completed	92	Dr. Frank Behrens	Nov 2019
NCT03000439		A Safety, Efficacy And Pharmacokinetics Study Of Tofacitinib In Pediatric Patients With sJIA	P3	completed	100	Pfizer	May 2018
NCT04311567	PULMORA	Effects of Tofacitinib vs Methotrexate on Rheumatoid Arthritis Interstitial Lung Disease	P4	terminated	3	Vastra Gotaland Region	Nov 2020
NCT06310057		Tofacitinib in the Treatment of Refractory Axial Spondyloarthritis Patients: A Dose Escalation Study	P4	completed	92	Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh	Jan 2022
NCT05048238		Evaluation of Tofacitinib in Prevention of Photosensitivity in Lupus	P1	completed	7	National Institute of Allergy and Infectious Diseases (NIAID)	Sep 2022
NCT04768504		Tofacitinib for the Treatment of Refractory Immune-related Colitis from Checkpoint Inhibitor Therapy- TRICK Study	P2	terminated	2	Khashayar Esfahani	Mar 2022
NCT06278402		Efficacy of Oral Tofacitinib in Moderate to Severe Alopecia Areata, Totalis and Universalis at Tertiary Care Hospital, Karachi.	P3	completed	30	Jinnah Hospital	Jul 2023
NCT05431283	RETUCAS	Real-world Effectiveness of Tofacitinib on Ulcerative Colitis Associated Spondyloarthropathy	—	unknown	100	Italian Group for the study of Inflammatory Bowel Disease (IG-IBD)	Apr 2022
NCT04925973	TRIUMPH	Tofacitinib for Hospitalized Acute Severe Ulcerative Colitis Management	P2	active not recruiting	24	McMaster University	Jun 2021
NCT04062695	PASTOR	Tofacitinib for Reduction of Spinal Inflammation in Patients With Psoriatic ArthritiS PresenTing With Axial InvOlvement	P2	unknown	80	Charite University, Berlin, Germany	Aug 2020
NCT04299971		Efficiency of Methotrexate and Tofacitinib in Mild and Moderate Patients	P4	unknown	130	Shanghai Zhongshan Hospital	Mar 2020
NCT04927000		The Role of Tofacitinib in Steroid Withdrawal in Rheumatoid Arthritis	P4	unknown	170	Second Affiliated Hospital, School of Medicine, Zhejiang University	May 2021
NCT03288324		Open-label Study of Tofacitinib for Moderate to Severe Skin Involvement in Young Adults With Lupus	P1/P2	completed	13	Children's Hospital Medical Center, Cincinnati	Aug 2017
NCT05087589		Efficacy, Safety and Immunological Evaluation of Tofacitinib in the Treatment of Primary Sjogren's Syndrome	P2	unknown	10	Peking University People's Hospital	Nov 2021
NCT05638932		Methodologies for Observational Studies Comparing Inpatient COVID-19 Treatments	—	completed	1,442	Aetion, Inc.	Jun 2020
NCT06157905		Efficacy and Safety of Oral Tofacitinib in the Treatment of Alopecia Areata	Early P1	completed	9	Services Institute of Medical Sciences, Pakistan	Aug 2022
NCT05487963		Tolerability and Effectiveness of CGB-500 Topical Ointment, 1% Tofacitinib, for the Treatment of Atopic Dermatitis	P1/P2	completed	40	CAGE Bio Inc.	Nov 2022
NCT04928066	TF	The Efficacy and Safety of Tofacitinib (TF) With Iguratimod (IGU) on RA	P4	completed	100	Qilu Hospital of Shandong University	Mar 2020
NCT03387423	ESCALATE-RA	Observational Study to Determine How Physicians Make Treatment Decisions in Patients Treated With Tofacitinib for Moderate to Severe Active Rheumatoid Arthritis	—	completed	1,459	Pfizer	Nov 2017
NCT05400889		Clinical Characteristics and Mechanism Research of Inhibitors of Janus Kinase in the Idiopathic Inflammatory Myopathies	P2	unknown	10	Peking University People's Hospital	Jun 2022
NCT05133297		The Safety and Efficacy of TLL-018 in Active Rheumatoid Arthritis	P2	completed	101	Hangzhou Highlightll Pharmaceutical Co., Ltd	Feb 2022
NCT04580277		Tofacitinib For Treatment Of Chronic Pouchitis	P2	terminated	6	Cedars-Sinai Medical Center	Jan 2021
NCT04175886	TOFAT	Effects of Tofacitinib on Body Composition, Bone Mineral Density and Bone Marrow Adiposity in Patients With Rheumatoid Arthritis: the TOFAT Project	—	completed	10	University Hospital, Lille	Feb 2020
NCT04613219		Correlation Between the Change of Peripheral Lymphocyte Subsets and Clinically Amyopathic Dermatomyositis Combined With Rapidly Progressive Interstitial Lung Disease	—	unknown	80	Jing Liang	Oct 2020
NCT05165771		Study to Evaluate Safety, Tolerability, and Efficacy of GS-5718 in Participants With Active Rheumatoid Arthritis Who Have an Inadequate Response to Disease-modifying Antirheumatic Drug(s) (bDMARDs) Treatment	P2	withdrawn	0	Gilead Sciences	Jul 2022
NCT03981900		IDentification of Factors Predictive of Tofacitinib's Survival in Patient With Rheumatoid Arthritis	—	completed	314	Pfizer	Jan 2019
NCT03970837	contRAst 2	Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic (cs)/Biologic (b) Disease Modifying Anti-rheumatic Drugs (DMARDs)	P3	terminated	1,764	GlaxoSmithKline	Jun 2019
NCT03980483	contRAst 1	Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate	P3	completed	1,537	GlaxoSmithKline	May 2019
NCT05728008		Retrospective Observational Comparison Study Between Ustekinumab and Tofacitinib as Third Line Therapy in a Multicenter Cohort of Patients With Refractory Ulcerative Colitis.	—	completed	100	IRCCS San Raffaele	Apr 2022
NCT04141904	TIDE	Tofacitinib in Depression (TIDE)	P1/P2	terminated	2	University of Oxford	Feb 2020
NCT04798287	STAR-RA-Cancer	Safety of TofAcitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA)-Cancer Endpoints	—	completed	105,711	Brigham and Women's Hospital	Mar 2021
NCT04799262		Tofacitinib as a GC Sparing Agent for Polymyalgia Rheumatica	P2	completed	14	RenJi Hospital	Jan 2021
NCT04413617		TO ASSESS THE EFFICACY AND SAFETY OF PF-06650833, PF-06651600, AND TOFACITINIB ALONE AND IN COMBINATION IN PARTICIPANTS WITH ACTIVE RHEUMATOID ARTHRITIS WITH AN INADEQUATE RESPONSE TO METHOTREXATE	P2	completed	460	Pfizer	Jul 2020
NCT03598959		Tofacitinib Combined With Chidamide in R/R ENKTCL	P2	unknown	20	Sichuan University	Jan 2019
NCT03011281		Effectiveness and Safety of Tofacitinib in Korean Patients With Rheumatoid Arthritis	—	unknown	378	Hanyang University	Sep 2016
NCT04772248	STAR-RA	Safety of TofAcitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA)- Cardiovascular Endpoints	—	completed	105,711	Brigham and Women's Hospital	Feb 2021
NCT04721821		Comparative Effectiveness Of Tumor Necrosis Factor Inhibitors And Tofacitinib Use In Earlier Lines Of Therapy And Use As Monotherapy.	—	completed	7,807	Pfizer	Jan 2021
NCT04034238		Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors	P1	completed	19	National Cancer Institute (NCI)	Aug 2019
NCT04985955		A Study Validating the Use of Candin as a Challenge Agent in Healthy Participants - Intervention Specific Appendix 3	P1	completed	12	Janssen Research & Development, LLC	Jul 2021
NCT04529876	DREAM	Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - Tofacitinib vs Abatacept	—	completed	29,464	Brigham and Women's Hospital	Aug 2020
NCT01932372		Tofacitinib (Xeljanz) Special Investigation for Rheumatoid Arthritis	—	completed	9,968	Pfizer	Jul 2013
NCT03793439		Tofacitinib Hypothesis-generating, Pilot Study for Corticosteroid-Dependent Sarcoidosis	P1	completed	5	Oregon Health and Science University	May 2019
NCT03910543		Open-label Trial of Tofacitinib in Cutaneous Sarcoidosis and Granuloma Annulare	P1	completed	15	Yale University	Apr 2019
NCT03486457		Efficacy And Safety Of Tofacitinib In Chinese Subjects With Active Psoriatic Arthritis	P3	completed	204	Pfizer	Aug 2018
NCT03580343		Tofacitinib for Inflammatory Eye Disease	P2	unknown	5	Washington University School of Medicine	Apr 2019
NCT04415151	I-TOMIC	Tofacitinib for Treatment of Moderate COVID-19	P2	terminated	24	Yale University	Oct 2020
NCT04973033		Effect of Tofacitinib in Treating ANCA-associated Vasculitis	N/A	completed	10	Shanghai Zhongshan Hospital	Dec 2019
NCT03800979		Effectiveness and Safety of Tofacitinib in Patients With Extensive and Recalcitrant Alopecia Areata	P4	completed	19	Institute of Dermatology, Thailand	Jan 2019
NCT04469114		Tofacitinib in Hospitalized Patients With COVID-19 Pneumonia	P3	completed	289	Hospital Israelita Albert Einstein	Sep 2020
NCT04552197		A Study of JNJ-64251330 in Healthy Participants	P1	completed	36	Janssen Research & Development, LLC	Sep 2020
NCT04468425		Tofacitinib Citrate Topical Gel 3.2% FDA BA Bridging Study	P1	completed	14	TWi Biotechnology, Inc.	Oct 2020
NCT04390061	TOFACoV-2	TOFAcitinib Plus Hydroxycloroquine vs Hydroxycloroquine in Patients With COVID-19 Interstitial Pneumonia	P2	unknown	116	Università Politecnica delle Marche	Jun 2020
NCT04412252		Safety and Efficacy of Tofacitinib in Hospitalized Participants With COVID-19 Pneumonia Who Are Receiving Standard of Care Therapy	P2	withdrawn	0	Pfizer	Jul 2020
NCT04464642		Tofacitinib Versus Methotrexate as the First Line DMARD in the Treatment of Rheumatoid Arthritis	P4	unknown	110	Dr. Mohammad Mamun Khan	Jul 2019
NCT03002649	STIR	Study of Tofacitinib in Refractory Dermatomyositis	P1	completed	10	Johns Hopkins University	Jan 2017
NCT04338711	QD	A Study In Adult Healthy Volunteers To Asses Once Daily (QD) Dosing With The Selected Age-Appropriate Modified Release (MR) Formulations	P1	completed	23	Pfizer	Jun 2020
NCT04750317	TOFA-COV-2	Efficacy and Safety of Tofacitinib in Patients With COVID-19 Pneumonia	P2	completed	414	I.M. Sechenov First Moscow State Medical University	May 2020
NCT03502616	AS	Efficacy and Safety of Tofacitinib in Subjects With Active Ankylosing Spondylitis (AS)	P3	completed	270	Pfizer	Jun 2018
NCT02092467	TNF	Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis	P4	completed	4,372	Pfizer	Mar 2014
NCT04332042		TOFAcitinib in SARS-CoV2 Pneumonia	P2	unknown	50	Università Politecnica delle Marche	Apr 2020
NCT03159936	DLE	Oral Tofacitinib in Adult Subjects With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE)	Early P1	terminated	5	Tufts Medical Center	Apr 2017
NCT03504072		Risk of Tuberculous and Other Infections in Patients of Spondyloarthritis Treated With Tofacitinib in Bangladesh	P4	unknown	174	Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh	Jan 2018
NCT04111614		A Study to Demonstrate the Equivalence of the Tofacitinib Oral Solution to the Tablet Formulation in Healthy Participants.	P1	completed	12	Pfizer	Oct 2019
NCT03274076	TOFA-SSc	Evaluation of Tofacitinib in Early Diffuse Cutaneous Systemic Sclerosis (dcSSc)	P1/P2	completed	15	University of Michigan	Sep 2017
NCT03736161	PsOLSET-BD	Safety and Efficacy of Tofacitinib vs Methotrexate in the Treatment of Psoriatic Arthritis	P3	completed	61	Globe Pharmaceuticals Limited	Sep 2017
NCT01976364	OPAL BALANCE	Open-Label Extension Study Of Tofacitinib In Psoriatic Arthritis	P3	completed	686	Pfizer	Feb 2014
NCT02592434		Efficacy Study Of Tofacitinib In Pediatric JIA Population	P3	completed	225	Pfizer	Jun 2016
NCT03868072		Study to Evaluate the Bioequivalence of Pfizer Korea Inc. "XELJANZ 5Mg Tablet" in Healthy Volunteers	P1	completed	40	Chong Kun Dang Pharmaceutical	Feb 2019
NCT04403776		PK and Bioavailability Comparison of Tofacitinib Between a Modified Release and The Immediate Release Formulation	P1	completed	26	Pfizer	Dec 2018
NCT03738956		Safety and Efficacy of Tofacitinib in the Treatment of NSAID Refractory Axial Spondyloarthritis:A Clinical Trial	P2/P3	unknown	30	Globe Pharmaceuticals Limited	Sep 2017
NCT02812342		Topical Tofacitinib for the Treatment of Alopecia Areata and Its Variants	P2	completed	10	Yale University	Sep 2016
NCT02996500		Safety and Efficacy of Pf-06650833 In Subjects With Rheumatoid Arthritis, With An Inadequate Response To Methotrexate	P2	completed	269	Pfizer	Nov 2016
NCT02535689		Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Systemic Lupus Erythematosus	P1	completed	34	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	Aug 2015
NCT02566967	LDA	An Evaluation of the Optimal Dose of Tofacitinib Needed to Achieve Low Disease Activity (LDA) or Clinical Remission in Patients With Active Rheumatoid Arthritis (RA) as Measured From a Clinical and Structural Perspective	P3	completed	20	Norman B. Gaylis, MD	May 2015
NCT02299297		Study To Evaluate The Efficacy Of Tofacitinib In Moderate To Severe Alopecia Areata, Totalis And Universalis	P2	completed	12	Columbia University	Jan 2015
NCT03112148		PK Study in Adult Healthy Volunteers to Assess QD Dosing With the Selected Age-appropriate MR Formulations	P1	completed	24	Pfizer	Sep 2017
NCT03103412	UC	TD-3504 SAD in Healthy Subjects and Subjects With Ulcerative Colitis (UC)	P1	completed	32	Theravance Biopharma	May 2017
NCT02321930		Musculoskeletal Ultrasound Assessment of Therapeutic Response of Tofacitinib in Rheumatoid Arthritis Patients	P4	completed	37	University of California, Los Angeles	Feb 2016
NCT02281552		A Study To Evaluate The Safety And Efficacy Of Tofacitinib Modified Release Tablets Compared To Tofacitinib Immediate Release Tablets In Adult Patients With Rheumatoid Arthritis	P3	completed	209	Pfizer	Nov 2014
NCT02187055	ORAL STRATEGY	An Efficacy And Safety Study Evaluating Tofacitinib With And Without Methotrexate Compared To Adalimumab With Methotrexate	P4	completed	1,152	Pfizer	Aug 2014
NCT01882439	OPAL BEYOND	Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors	P3	completed	395	Pfizer	Aug 2013
NCT01877668	OPAL BROADEN	Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study	P3	completed	422	Pfizer	Jan 2014
NCT02312882		Tofacitinib for the Treatment of Alopecia Areata and Its Variants	N/A	completed	40	Stanford University	Dec 2014
NCT02487433		A Study To Evaluate The Effect Of Food On The Behavior of Tofacitinib Modified Release 22 Milligram Tablets In Healthy Volunteers	P1	completed	18	Pfizer	Jun 2015
NCT02197455		Tofacitnib for the Treatment of Alopecia Areata and Variants	P2	completed	30	Yale University	Jul 2014
NCT02147587		A Study to Assess Immune Response Following Zoster Vaccination to Subjects With Rheumatoid Arthritis Receiving Tofacitinib or Placebo With Background Methotrexate	P2	completed	112	Pfizer	Jun 2014
NCT01458951	OCTAVE	A Study To Evaluate Both The Efficacy and Safety Profile of CP-690,550 In Patients With Moderately to Severely Active Ulcerative Colitis	P3	completed	547	Pfizer	Jun 2012
NCT01465763	OCTAVE	A Study Evaluating The Efficacy And Safety Of CP-690,550 In Patients With Moderate To Severe Ulcerative Colitis	P3	completed	614	Pfizer	Apr 2012
NCT01786668		Dose-Ranging Study Of Tofacitinib In Adults With Active Ankylosing Spondylitis	P2	completed	208	Pfizer	Apr 2013
NCT02193815		A 12 Day Study To Evaluate A Topical Drug To Treat Plaque Psoriasis	P1	completed	15	Pfizer	Sep 2014
NCT02001181		Tofacitinib Ointment For Atopic Dermatitis (Atopic Eczema)	P2	completed	69	Pfizer	Dec 2013
NCT01831466		Tofacitinib Ointment For Chronic Plaque Psoriasis	P2	completed	476	Pfizer	May 2013
NCT02084875		A Study To Evaluate The Effect Of Food On The Behavior Of Tofacitinib Modified Release 11 Milligram Tablets In Healthy Western And Japanese Volunteers	P1	completed	24	Pfizer	Apr 2014
NCT01741493		A Study in Healthy Adults and Adult Subjects With Rheumatoid Arthritis to Evaluate the Safety, Tolerability and Pharmacokinetics After Multiple Doses of ABT-494	P1	completed	67	AbbVie (prior sponsor, Abbott)	Nov 2012
NCT01710046		Study Of The Mechanism Of Action Of CP-690,550 In The Skin Of Subjects With Moderate To Severe Chronic Plaque Psoriasis	P2	completed	12	Pfizer	Mar 2013
NCT01164579	MRI	Effects of Tofacitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA)	P2	completed	109	Pfizer	Oct 2010
NCT01731327	PK	A Phase 1 Study To Evaluate The Pharmacokinetics (PK), Safety, And Bioavailability Of A Modified-Release (MR) Formulation Of Tofacitinib In Healthy Volunteers	P1	completed	20	Pfizer	Nov 2012
NCT01599377		Tofacitinib Bioequivalence Study Comparing Tablets And Capsules	P1	completed	50	Pfizer	May 2012
NCT01375127		Collection of Follow-up Data From CP-690,550-treated Kidney Transplant Recipients	—	completed	83	Pfizer	Aug 2011
NCT01499004		A Phase 1 Study To Evaluate The Pharmacokinetics And Safety Of Three Modified Release And One Immediate Release Formulations Of Tofacitinib (CP-690,550) In Healthy Volunteers	P1	completed	30	Pfizer	Nov 2011
NCT01745055		Co-Administration Of Methotrexate And CP-690,550	P1	completed	12	Pfizer	Apr 2005
NCT01736696		Multiple Dose Escalation Study In Medically Stable Subjects With Psoriasis	P1	completed	59	Pfizer	Nov 2002

Tofacitinib clinical trials: frequently asked questions

How many Tofacitinib clinical trials are there?: 189 Tofacitinib clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 32 are actively recruiting participants. 93 are marked completed.
Are Tofacitinib clinical trials recruiting in 2026?: Yes — 32 Tofacitinib trials are actively recruiting in 2026, with 47 U.S. sites across 24 states. See the recruiting trials and the per-state site list further down this page.
What conditions is Tofacitinib being studied for?: Tofacitinib is being studied for Rheumatoid Arthritis, Ulcerative Colitis, Healthy, Psoriatic Arthritis, Alopecia Areata and 142 more. The trials are grouped by indication on this page.
What phase is Tofacitinib in?: Tofacitinib clinical trials span 35 Phase 4, 27 Phase 3, 49 Phase 2, 25 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
Who sponsors Tofacitinib clinical trials?: The lead sponsor across the most Tofacitinib trials is Pfizer, with 101 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.

Sources and methodology

Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Tofacitinibas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.

Last refreshed June 16, 2026.

Related pages on Hipa.ai:

Tofacitinib overview Tofacitinib evidence & publications